Dark Horse Consulting Group Inc.
Sheryl Hancock-Andersen has a diverse and extensive work experience spanning over three decades. Sheryl most recently holds the position of Vice President of Finance at Dark Horse Consulting Group Inc., where they have been working since January 2023. Prior to this role, they served as the Senior Controller at Dark Horse Consulting Group Inc. from June 2021 to January 2023. Before joining Dark Horse Consulting Group Inc., Sheryl worked at Engine Room as a Senior Controller from January 2020 to June 2021.
In 2019, they were appointed as the Director of SEC Reporting at 8x8, where they worked from June to December. From 2017 to 2019, they held the position of Director, Assistant Controller at Asterias Biotherapeutics. Prior to that, Sheryl worked as the Director of SEC Reporting and Compliance at Gigamon from November 2014 to March 2017. Sheryl then joined TiVo as the Senior Director of External Reporting and Internal Audit, where they worked for almost a decade, from May 2005 to October 2014.
Sheryl began their career as an Accounting Manager at Versant Corporation from 2000 to 2005. Sheryl gained early experience at Philips as a Financial Analyst from November 1999 to December 2000 and at Digital Link Corporation as a Cost Accountant/General Accountant from September 1997 to November 1999. Their first professional role was as an Accounting Clerk at Glasforms from October 1992 to January 1997.
Sheryl Hancock-Andersen attended Piedmont Hills High School from 1980 to 1984. Following their high school education, they enrolled at San Jose State University from 1998 to 2001, although the specific degree and field of study they pursued were not specified.
This person is not in any offices
Dark Horse Consulting Group Inc.
AT DARK HORSE CONSULTING, we work to accelerate cell and gene therapies through our unmatched expertise. Our consulting team has extensive CGT industry experience with knowledge spanning manufacturing, process development, comparability, analytical dev, quant modeling, quality systems, regulatory support, preclinical dev, device dev, program management, facility design and enginnering, market research, and due diligence and business strategy. Many of our consultants also bring experience from adjacent, more mature, sectors, including traditional biologics, small molecules, medical devices, and management consulting. Client requests range from scientific expertise to tactical needs to strategic considerations to business development. We understand the unique challenges faced by Cell and Gene Therapy developers like none other. We apply best practices from across this and other industries to address the needs of our clients, who range from biopharmaceutical companies to tools & tech providers to investment firms.